# IDEAYA Biosciences

Source: https://onco.cc/companies/ideaya-biosciences/  
OnCo record `ideaya-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IDEAYA Biosciences develops cancer drugs matched to the genetic make-up of a patient's tumour. Its most advanced drug, darovasertib, met the main goal of a registrational trial in people whose uveal melanoma, a rare eye cancer, had spread, and the company is filing for US approval.

## Summary

IDEAYA Biosciences is a South San Francisco precision oncology company working on synthetic lethality, metabolic and epigenetic tumour dependencies. Its lead programme, darovasertib (a PKC inhibitor), is in phase 3 registrational trials in metastatic uveal melanoma and, with crizotinib, as adjuvant therapy in primary uveal melanoma (the OptimUM-11 trial with Servier dosed its first patient in September 2026), plus phase 2 studies in GNAQ/11-mutant tumours. In August 2026 the company reported that the registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma met its primary endpoint, with median progression-free survival of 6.9 months against 3.1 months on investigator's choice of treatment (blinded central review, hazard ratio 0.42), and that a new drug application was under way under the FDA's Real-Time Oncology Review, with completion expected in the second half of 2026. Other programmes include IDE849, a DLL3-directed topoisomerase 1 antibody-drug conjugate in phase 1/2 for small cell lung cancer, for which the company reported FDA agreement on a phase 3 design in August 2026; IDE034 (B7H3/PTK7 ADC); IDE161 (PARG inhibitor); IDE397 (MAT2A inhibitor, phase 2) and IDE892 (PRMT5) for MTAP-deleted cancers; and IDE574 (KAT6/7). IDEAYA listed on Nasdaq in May 2019, raising 57.5 million US dollars gross in its IPO.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://www.ideayabio.com/
- Ticker: IDYA

## Notes

- Later follow-on offerings and the GSK partnership were not sourced. Founding year not sourced. Pancreatic cancer tag rests on an August 2026 news headline about a Genentech clinical collaboration in MTAP-deleted KRAS G12D pancreatic cancer. OptimUM-02 figures and NDA status come from the second-quarter 2026 results release of 4 August 2026; the release does not name the combination partner in the passages read. IDEAYA's SEC filings from January 2025 to October 2026 show no acquisition or merger.

## Sources

- Official website: https://www.ideayabio.com/
- Pipeline: https://www.ideayabio.com/pipeline/
- Q2 2026 results and OptimUM-02 outcome (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-ex99_1.htm
- IPO closing press release (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex991.htm
- Investor news releases: https://ir.ideayabio.com/news-releases

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- drugs: [Darovasertib](https://onco.cc/drugs/darovasertib/)
- trials: [(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma](https://onco.cc/trials/nct05907954/), [A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer](https://onco.cc/trials/nct07174583/), [A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors](https://onco.cc/trials/nct06710847/), [IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma](https://onco.cc/trials/nct05987332/), [Neoadjuvant Darovasertib in Primary Uveal Melanoma](https://onco.cc/trials/nct07015190/), [Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma](https://onco.cc/trials/nct07804186/), [Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions](https://onco.cc/trials/nct03947385/)

---
JSON: https://onco.cc/api/v1/entities/ideaya-biosciences.json